Targeting MDM2–p53 Axis through Drug Repurposing for Cancer Therapy: A Multidisciplinary Approach
ACS Omega · 2023-09-26 · 8 (38) · 34583-34596
DOI: 10.1021/acsomega.3c03471 ↗At a glance
Journal article in ACS Omega, published online on 2023-09-15. Written by Naeem Abdul Ghafoor and 1 co-authors. Institution: Department of Molecular Biology and Genetics, Graduate School of Natural and Applied Sciences, Mugla Sitki Kocman University, 48000 Mugla, Turkey. Cited 19 times so far (Crossref); 63 references. The full text is freely available (open access, CC BY 4.0). Funded by: Research Support and Funding Office, Mugla Sitki Ko?man University.
Abstract (original language)
Cancer remains a major cause of morbidity and mortality worldwide, and while current therapies, such as chemotherapy, immunotherapy, and cell therapy, have been effective in many patients, the development of novel therapeutic options remains an urgent priority. Mouse double minute 2 (MDM2) is a key regulator of the tumor suppressor protein p53, which plays a critical role in regulating cellular growth, apoptosis, and DNA repair. Consequently, MDM2 has been the subject of extensive research aimed at developing novel cancer therapies. In this study, we employed a machine learning-based approach to establish a quantitative structure-activity relationship model capable of predicting the potential in vitro efficacy of small molecules as MDM2 inhibitors. Our model was used to screen 5883 FDA-approved drugs, resulting in the identification of promising hits that were subsequently evaluated using molecular docking and molecular dynamics simulations. Two antihistamine drugs, cetirizine (CZ) and rupatadine (RP), exhibited particularly favorable results in the initial in silico analyses. To further assess their potential use as the activators of the p53 pathway, we investigated the antiproliferative capability of the abovementioned drugs on human glioblastoma and neuroblastoma cell lines. Both the compounds exhibited significant antiproliferative effects on the abovementioned cell lines in a dose-dependent manner. The half-maximal inhibitory concentration (IC50) of CZ was found to be 697.87 and 941.37 μM on U87 and SH-SY5Y cell lines, respectively, while the IC50 of RP was found to be 524.28 and 617.07 μM on the same cell lines, respectively. Further investigation by quantitative reverse transcriptase polymerase chain reaction analysis revealed that the CZ-treated cell lines upregulate the expression of the p53-regulated genes involved in cell cycle arrest, apoptosis, and DNA damage response compared to their respective vehicle controls. These findings suggest that CZ activates the p53 pathway by inhibiting MDM2. Our results provide compelling preclinical evidence supporting the potential use of CZ as a modulator of the MDM2-p53 axis and its plausible repurposing for cancer treatment.
Authors and institutions
- Department of Molecular Biology and Genetics, Graduate School of Natural and Applied Sciences, Mugla Sitki Kocman University, 48000 Mugla, Turkey.
- Department of Molecular Biology and Genetics, Faculty of Science, Mugla Sitki Kocman University, 48000 Mugla, Turkey.
ORCID profiles: Aysegul Yildiz
Funding
- Research Support and Funding Office, Mugla Sitki Ko?man University
Cite
APA
Ghafoor, N. A., & Yildiz, A. (2023). Targeting MDM2–p53 Axis through Drug Repurposing for Cancer Therapy: A Multidisciplinary Approach. ACS Omega, 8(38), 34583-34596. https://doi.org/10.1021/acsomega.3c03471
Vancouver
Ghafoor NA, Yildiz A. Targeting MDM2–p53 Axis through Drug Repurposing for Cancer Therapy: A Multidisciplinary Approach. ACS Omega. 2023;8(38):34583-34596. doi:10.1021/acsomega.3c03471
BibTeX
@article{Ghafoor2023,
author = {Ghafoor, Naeem Abdul and Yildiz, Aysegul},
title = {Targeting MDM2–p53 Axis through Drug Repurposing for Cancer Therapy: A Multidisciplinary Approach},
journal = {ACS Omega},
year = {2023},
volume = {8},
number = {38},
pages = {34583--34596},
doi = {10.1021/acsomega.3c03471}
}
EUVIMED